Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18


State of play and clinical prospects of antibody gene transfer.

Hollevoet K, Declerck PJ.

J Transl Med. 2017 Jun 7;15(1):131. doi: 10.1186/s12967-017-1234-4. Review.


Engineering humoral immunity as prophylaxis or therapy.

Deal CE, Balazs AB.

Curr Opin Immunol. 2015 Aug;35:113-22. doi: 10.1016/j.coi.2015.06.014. Epub 2015 Jul 14. Review.


Characterization of four new monoclonal antibodies against the distal N-terminal region of PrP(c).

Didonna A, Venturini AC, Hartman K, Vranac T, Čurin Šerbec V, Legname G.

PeerJ. 2015 Mar 19;3:e811. doi: 10.7717/peerj.811. eCollection 2015.


Prion protein-specific antibodies-development, modes of action and therapeutics application.

Rovis TL, Legname G.

Viruses. 2014 Oct 1;6(10):3719-37. doi: 10.3390/v6103719. Review.


Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis.

Patel P, Kriz J, Gravel M, Soucy G, Bareil C, Gravel C, Julien JP.

Mol Ther. 2014 Mar;22(3):498-510. doi: 10.1038/mt.2013.239. Epub 2013 Oct 17.


Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Huang L, Su X, Federoff HJ.

Int J Mol Sci. 2013 Sep 17;14(9):19109-27. doi: 10.3390/ijms140919109. Review.


Gene-based antibody strategies for prion diseases.

Cardinale A, Biocca S.

Int J Cell Biol. 2013;2013:710406. doi: 10.1155/2013/710406. Epub 2013 Aug 21. Review.


Detection and control of prion diseases in food animals.

Hedlin P, Taschuk R, Potter A, Griebel P, Napper S.

ISRN Vet Sci. 2012 Feb 29;2012:254739. doi: 10.5402/2012/254739. Print 2012.


Gene therapy for misfolding protein diseases of the central nervous system.

San Sebastian W, Samaranch L, Kells AP, Forsayeth J, Bankiewicz KS.

Neurotherapeutics. 2013 Jul;10(3):498-510. doi: 10.1007/s13311-013-0191-8. Review.


Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents.

Karapetyan YE, Sferrazza GF, Zhou M, Ottenberg G, Spicer T, Chase P, Fallahi M, Hodder P, Weissmann C, Lasmézas CI.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):7044-9. doi: 10.1073/pnas.1303510110. Epub 2013 Apr 1.


Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice.

Moda F, Vimercati C, Campagnani I, Ruggerone M, Giaccone G, Morbin M, Zentilin L, Giacca M, Zucca I, Legname G, Tagliavini F.

Prion. 2012 Sep-Oct;6(4):383-90. doi: 10.4161/pri.20197. Epub 2012 Jul 30.


Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment.

Skrlj N, Vranac T, Popović M, Curin Šerbec V, Dolinar M.

PLoS One. 2011 Jan 20;6(1):e15783. doi: 10.1371/journal.pone.0015783.


A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines.

Jones DR, Taylor WA, Bate C, David M, Tayebi M.

PLoS One. 2010 Mar 22;5(3):e9804. doi: 10.1371/journal.pone.0009804.


Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease.

Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, Federoff HJ, Bowers WJ.

Mol Ther. 2009 Dec;17(12):2031-40. doi: doi:10.1038/mt.2009.174. Epub 2009 Jul 28.


Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions.

Song CH, Honmou O, Ohsawa N, Nakamura K, Hamada H, Furuoka H, Hasebe R, Horiuchi M.

J Virol. 2009 Jun;83(11):5918-27. doi: 10.1128/JVI.00165-09. Epub 2009 Mar 18.


Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.

Maguire-Zeiss KA, Federoff HJ.

J Neuroimmune Pharmacol. 2009 Sep;4(3):298-308. doi: 10.1007/s11481-008-9133-3. Epub 2008 Oct 18. Review.


alpha-Synuclein: a therapeutic target for Parkinson's disease?

Maguire-Zeiss KA.

Pharmacol Res. 2008 Nov-Dec;58(5-6):271-80. doi: 10.1016/j.phrs.2008.09.006. Epub 2008 Sep 16. Review.

Supplemental Content

Support Center